TW201613891A - Substituted prolines / piperidines as orexin receptor antagonists - Google Patents

Substituted prolines / piperidines as orexin receptor antagonists

Info

Publication number
TW201613891A
TW201613891A TW104104642A TW104104642A TW201613891A TW 201613891 A TW201613891 A TW 201613891A TW 104104642 A TW104104642 A TW 104104642A TW 104104642 A TW104104642 A TW 104104642A TW 201613891 A TW201613891 A TW 201613891A
Authority
TW
Taiwan
Prior art keywords
disorder
orexin receptor
compounds
disease
treatment
Prior art date
Application number
TW104104642A
Other languages
English (en)
Chinese (zh)
Inventor
Theodore M Kamenecka
Yuanjun He
Rong Jiang
William Nguyen
Xinyi Song
Robert Jason Herr
Keith Barnes
Steven D Young
Qin Jiang
Original Assignee
Eolas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/179,432 external-priority patent/US9499517B2/en
Priority claimed from US14/460,289 external-priority patent/US9440982B2/en
Application filed by Eolas Therapeutics Inc filed Critical Eolas Therapeutics Inc
Publication of TW201613891A publication Critical patent/TW201613891A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW104104642A 2014-02-12 2015-02-11 Substituted prolines / piperidines as orexin receptor antagonists TW201613891A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/179,432 US9499517B2 (en) 2012-02-07 2014-02-12 Substituted prolines / piperidines as orexin receptor antagonists
US201462037471P 2014-08-14 2014-08-14
US14/460,289 US9440982B2 (en) 2012-02-07 2014-08-14 Substituted prolines/piperidines as orexin receptor antagonists

Publications (1)

Publication Number Publication Date
TW201613891A true TW201613891A (en) 2016-04-16

Family

ID=53800603

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104104642A TW201613891A (en) 2014-02-12 2015-02-11 Substituted prolines / piperidines as orexin receptor antagonists

Country Status (3)

Country Link
TW (1) TW201613891A (fr)
UY (1) UY35993A (fr)
WO (1) WO2015123355A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2491038B1 (fr) 2009-10-23 2016-04-06 Janssen Pharmaceutica N.V. Octahydropyrrolo[3,4-c]pyrroles disubstitués en tant que modulateurs de récepteur d'orexine
CA2863413A1 (fr) 2012-02-07 2013-08-15 Eolas Therapeutics, Inc. Piperidines/prolines substituees en tant qu'antagonistes du recepteur de l'orexine
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
AR101558A1 (es) 2014-08-13 2016-12-28 Eolas Therapeutics Inc Difluoropirrolidinas como moduladores del receptor de orexina
GB201601703D0 (en) * 2016-01-29 2016-03-16 C4X Discovery Ltd Therapeutic compounds
TWI710557B (zh) * 2016-02-12 2020-11-21 美商伊歐拉斯治療學公司 作為食慾素受體調節劑之經鹵素取代之六氫吡啶
CA2960253A1 (fr) 2016-03-10 2017-09-10 Janssen Pharmaceutica Nv Methodes de traitement de la depression au moyen d'antagonistes du recepteur orexine-2
AU2017242027B2 (en) * 2016-04-01 2020-10-08 Recurium Ip Holdings, Llc Estrogen receptor modulators
CN108239019B (zh) * 2016-12-27 2021-05-04 浙江医药股份有限公司新昌制药厂 一种(2s,5s或5r)-n-叔丁氧羰基-5-羟基-2-哌啶甲酸乙酯的合成方法
PL3619199T3 (pl) * 2017-05-03 2021-12-20 Idorsia Pharmaceuticals Ltd Wytwarzanie pochodnych kwasu 2-([1,2,3]triazol-2-ilo)­-benzoesowego
CN111138413B (zh) * 2018-11-01 2022-11-04 江苏豪森药业集团有限公司 一种细胞周期蛋白依赖性激酶抑制剂的制备方法及其中间体
TW202400149A (zh) * 2022-05-13 2024-01-01 瑞士商愛杜西亞製藥有限公司 經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003262516A1 (en) * 2002-09-18 2004-04-08 Glaxo Group Limited N-aroyl cyclic amines as orexin receptor antagonists
CA2863413A1 (fr) * 2012-02-07 2013-08-15 Eolas Therapeutics, Inc. Piperidines/prolines substituees en tant qu'antagonistes du recepteur de l'orexine
US9440982B2 (en) * 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists

Also Published As

Publication number Publication date
UY35993A (es) 2015-08-31
WO2015123355A1 (fr) 2015-08-20

Similar Documents

Publication Publication Date Title
TW201613891A (en) Substituted prolines / piperidines as orexin receptor antagonists
BR112014019426A8 (pt) Prolinas/ piperidinas substituídas como antagonistas do receptor de orexina
TN2011000171A1 (en) Isonicotinamide orexin receptor antagonists
IL201790A0 (en) Pyridyl piperidine orexin receptor antagonists
IN2014CN02515A (fr)
WO2012009258A3 (fr) Modulateurs des récepteurs à la galanine peptidomimétiques
WO2008008551A3 (fr) Prolines bis-amides substituées en 2 antagonistes du récepteur de l'oréxine
WO2007126934A3 (fr) Antagonistes des récepteurs de l'orexine sous forme de composés amidoéthylthioéther
MX2009005712A (es) Antagonistas de receptor de orexina de diazepam sustituido.
PL2049529T3 (pl) Podstawione związki diazepanowe - antagoniści receptora oreksyny
WO2007126935A3 (fr) Antagonistes des récepteurs de l'orexine sous forme de composés diazépane
BR112013029673A2 (pt) antagonistas do receptor cb1
IN2015DN00957A (fr)
WO2009149485A3 (fr) Composés destinés au traitement des amyloïdoses
MX2020013099A (es) Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina.
ATE455776T1 (de) Nikotinische alpha-7-rezeptorliganden gegen erkrankungen des zns
TN2012000434A1 (en) Biparatopic abeta binding polypeptides
WO2012013282A8 (fr) Carboxamides azahétérocycliques bicycliques en tant qu'inhibiteurs de la kinase p70s6k
CY1118848T1 (el) Ενωσεις 1,3-οξαζολιδινης ή 1,3-οξαζινανης ως ανταγωνιστες υποδοχεα ορεξινης
EA201400969A1 (ru) Новые терапевтические подходы для лечения болезни паркинсона
WO2014145485A3 (fr) Modulateurs de map kinase et utilisations de ceux-ci
SG179203A1 (en) Novel arylated camphenes, processes for their preparation and uses thereof
MA37700B1 (fr) N-[4-(quinolin-4-yloxy)cyclohexyl(méthyl)](hétéro)arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments
WO2015013187A8 (fr) Composés épargnant les ppar pour le traitement de maladies métaboliques
MX363632B (es) Derivados de pirroloquinolina como antagonistas de 5-ht6, metodo de preparacion y uso de los mismos.